Abstract 607P
Background
Melanoma brain metastasis has very poor prognosis, although recent treatment advances, including immune checkpoint inhibitors and targeted therapy, have improved the prognosis. We investigated the survival of Asian patients with melanoma brain metastasis and the effectiveness of radiotherapy and systemic therapies.
Methods
We retrospectively reviewed the survival rates of patients diagnosed with melanoma brain metastasis between January 2011 and December 2021 at the National Cancer Center Hospital in Tokyo, Japan. In addition, we identified factors associated with survival using Cox regression analysis.
Results
A total of 135 patients were included. The median overall survival after melanoma brain metastasis diagnosis was 7.8 months (95% confidence interval [CI] 6.1–9.6). The 6-month and 1-year survival rates were 60.7% and 34.8%, respectively. We identified the prognostic factors of melanoma brain metastasis, including non-acral primary location, low serum LDH levels, systemic therapy of single-agent immune check point inhibitors or targeted therapies, and radiotherapy of stereotactic irradiation. On the other hand, We found no significant difference in effectiveness between single-agent immune check point inhibitors, the combination of immune check point inhibitors, and targeted therapies.
Conclusions
We retrospectively investigated the survival of patients with melanoma brain metastasis at our facility. The survival of Asian patients with melanoma brain metastasis is relatively poor compared to that of Caucasian patients. Immune check point inhibitor, targeted therapy, and radiotherapy of stereotactic irradiation were associated with improved survival; however, we found no significant superiority of the combination of immune check point inhibitors over single-agent immune check point inhibitor or targeted therapy in terms of effectiveness. Further investigations using larger cohorts, multicenter analyses, and prospective studies are necessary to assess the effectiveness of systemic therapy in Asian patients with melanoma brain metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dermatologic oncology department in National Cancer Center Hospital.
Funding
Has not received any funding.
Disclosure
N. Yamazaki: Financial Interests, Personal, Advisory Board: Ono, Chugai; Financial Interests, Personal, Invited Speaker: Ono, Bristol Myers Squibb, Novartis, MSD, Maruho; Financial Interests, Institutional, Research Grant: Ono, Bristol Myers Squibb, Novartis, Amgen. K. Namikawa: Financial Interests, Personal, Advisory Board: MSD, Novartis; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb, Novartis, MSD, Ono. All other authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract